In Brief: Ciba Corning
This article was originally published in The Gray Sheet
Ciba Corning: Introduces the ACS PSA2 test for prostate specific antigen. The test, used in the management of prostate cancer patients, is the second PSA assay for use on the firm's ACS:180 testing system. Capable of providing initial results in 15 minutes and offering a throughput of up to 180 tests per hour, the ACS PSA2 also features "a direct measurement range up to 135 ng/mL with automated dilution expanding the routine measurable range to 2,700 ng/mL." Ciba Corning introduced its initial ACS test for PSA in September 1994 following premarket approval for use of the test in prostate cancer management ("The Gray Sheet" Sept. 26, 1994, In Brief)...
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.